Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board
May 20 2024 - 9:03AM
Business Wire
Michael Grosso, Daiichi Sankyo Global Head of
Specialty Medicine Clinical Development, Joins Perosphere’s
Advisory Board to Support Company Innovation
Perosphere Technologies (Perosphere Technologies Inc.), a
private medical technologies company focused on developing
next-generation coagulation diagnostics, today announced Michael A.
Grosso, MD, FACS, joins its Advisory Board. As a seasoned
pharmaceutical industry executive who helped lead Daiichi Sankyo’s
direct oral anticoagulant (DOAC) Phase 3 clinical development, and
former academic cardiothoracic surgeon, Dr. Grosso will support
Perosphere’s mission to revolutionize patient care through the
development and commercialization of innovative diagnostic
tools.
“We are thrilled to welcome Dr. Michael Grosso to Perosphere’s
Advisory Board,” said Dr. Sasha Bakhru, CEO of Perosphere
Technologies. “His knowledge of DOACs and experience in developing
therapeutic solutions for patients fully aligns with Perosphere’s
mission to offer a complete diagnostic picture of a patient’s
coagulation status. His extensive expertise, both in and out of the
operating room, and his commitment to cross-functional and
cross-cultural collaboration, will ensure that the needs of
physicians and patients are fully considered and incorporated into
product features and capabilities as we develop and promote the use
of Perosphere’s technology.”
Dr. Grosso brings over four decades of healthcare knowledge,
including expertise in cardiovascular, hematology, and thrombosis
therapeutic areas and in the development of medicines, to his role
on the Board. “The technology Perosphere is developing excites me
both as a physician and as a leader in clinical development. There
is a clear need for more and better point-of-care diagnostics in
the coagulation arena, both from a patient care perspective and for
use in clinical trials for more timely results. I am honored to
have been asked to join the Advisory Board in order to support
Perosphere’s great work,” said Dr. Grosso. “Finding ways for
physicians to diagnose more accurately and treat patients more
confidently have been key goals in my career that dovetail
perfectly with Perosphere’s important mission.”
After graduating from The Perelman School of Medicine at the
University of Pennsylvania, Dr. Grosso spent 11 years as a
cardiothoracic surgeon. He later joined Sanofi as a
Cardio/Thrombosis medical advisor before joining Daiichi Sankyo in
2010, where he took on a variety of medical leadership roles. Dr.
Grosso is responsible for the pre-clinical, clinical (Phase 1-4),
and lifecycle management of the specialty medicine portfolio
globally for the orphan/rare genetic disease, neurology,
inflammation, ophthalmology, cardiovascular/metabolic, and
thrombosis/thrombolysis/hemostasis therapeutic areas.
About Perosphere Technologies
Perosphere Technologies is changing the way decisions are made
for patients at risk of bleeding. A private medical technologies
company, Perosphere is focused on development and commercialization
of its novel PoC (point-of-care) Coagulometer, which informs
diagnosis, treatment, and prevention through precision data, made
immediately accessible to all. It is the only point-of-care
diagnostic tool that effectively and swiftly tests clotting times
across drug classes, including DOACs. The fast diagnosis and
related appropriate treatment decisions the PoC Coagulometer
enables will help establish a new standard of care in hospitals, at
the point-of-care, for patients at risk for bleeding and has the
potential to improve efficiency, provide significant cost savings,
and better patient outcomes. The PoC Coagulometer has a CE Mark in
the EU but is not yet cleared in the US.
For further information, contact us at info@perospheretech.com
or +1 (475) 218-4600.
www.perospheretech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240520203580/en/
Danny Sudwarts FINN Partners danny.sudwarts@finnpartners.com
+972 2 589 2018